Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Investing Activities (2018 - 2023)

Marker Therapeutics (MRKR) has disclosed Cash from Investing Activities for 6 consecutive years, with $18.8 million as the latest value for Q2 2023.

  • Quarterly Cash from Investing Activities rose 928.54% to $18.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2023, up 477.42% year-over-year, with the annual reading at $18.7 million for FY2023, 477.42% up from the prior year.
  • Cash from Investing Activities for Q2 2023 was $18.8 million at Marker Therapeutics, up from -$112608.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was $18.8 million in Q2 2023, with the low at -$4.1 million in Q4 2020.
  • Average Cash from Investing Activities over 5 years is $53332.5, with a median of -$286484.5 recorded in 2019.
  • The sharpest move saw Cash from Investing Activities plummeted 31778.1% in 2020, then soared 928.54% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$12862.0 in 2019, then tumbled by 31778.1% to -$4.1 million in 2020, then skyrocketed by 91.47% to -$349843.0 in 2021, then surged by 63.6% to -$127342.0 in 2022, then surged by 14845.12% to $18.8 million in 2023.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $18.8 million, -$112608.0, and -$127342.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.